6:11 AM ET
8-K
Business Update
Interpace Biosciences Business Update
Interpace Biosciences announced preliminary unaudited revenue for the third quarter of 2026, expecting a range of $10.1 million to $10.4 million. This represents approximately 15% to 18% year-over-year growth compared to Q3 2025. The results are preliminary and subject to final quarter-end closing procedures.
- Term
- Q3 2026